ストックスクリーナーアプリを入手
1.19
3.25%
-0.04
プレマーケット:
1.18
-0.01
-0.84%
前日終値:
$1.23
開ける：
$1.19
24時間の取引高:
95,318
Relative Volume:
0.03
時価総額：
$4.99M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-16.78%
1か月 パフォーマンス:
-38.66%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.1292
$1.27
1週間の範囲:
$1.06
$1.40
52週間の値動き範囲:
$0.77
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
PLRZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.19 | 4.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Polyrizon Ltd (PLRZ) 最新ニュース
Polyrizon files patent for nasal drug delivery tech - MSN
Game-Changing Nasal Drug Tech Could Transform Treatment of Seizures and Overdoses - StockTitan
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - The Manila Times
Polyrizon Ltd. Commences GMP Manufacturing Preliminary Process for Its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - Marketscreener.com
Polyrizon Advances PL-14 Allergy Blocker Manufacturing, Eyes $23B Nasal Spray Market - StockTitan
Polyrizon appoints new board member Liron Carmel - MSN
Polyrizon Ltd. Approves the Appointment of Liron Carmel to its Board -January 21, 2025 at 04:15 pm EST - Marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Polyrizon (PLRZ) Stock Climbs After Patent Publication Update - Stocks Telegraph
Polyrizon Shares Rise After Publication of National Patent Application - MarketWatch
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today? - Benzinga
Patents and new EV’s have these small caps perking - RagingBull
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - The Manila Times
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
Full Stock Market News from 2024-12-21 - StockTitan
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com India
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial - MSN
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs - The Manila Times
Polyrizon Strengthens Clinical Leadership Ahead of Key 2025 PL-14 Trial, Appoints Regulatory Expert - StockTitan
U.S. Stocks Drop Sharply with Losses Across Major Sectors, Amazon and American Express Lead Declines - mediahousepress
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com India
Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus.com
TFSA: 3 Top TSX Stocks for Your $7,000 Contribution - Yahoo Canada Finance
Wall Street-Heavily Traded - WDRB
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Strategic DealSends Polyrizon (PLRZ) Shares To New Heights - Stocks Telegraph
Stellantis moves up launch of hybrid Ramcharger as EV demand cools - Yahoo Canada Finance
Polyrizon Shares Surge on Impending Clinical Trial - MarketWatch
What's Going On With Polyrizon Shares Wednesday?Polyrizon (NASDAQ:PLRZ) - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Biotechs and nuclear power for AI in play today 📈 - RagingBull
Artificial Intelligence (AI) News Live Feed - StockTitan
Polyrizon's Moving Forward with Expected 2025 Clinical TrialEntered Manufacturing Agreement for its PL-14 Allergy Blocker - The Manila Times
Polyrizon Partners with EU Manufacturing Giant for Novel Allergy Blocker Clinical Production - StockTitan
OPEC+ wary of renewed US oil output rise under Trump, sources say - Yahoo Canada Finance
Oil sags on soft Chinese spending, investor pause before US Fed rate move - Yahoo Canada Finance
Federal Reserve is likely to slow its rate cuts with inflation pressures still elevated - Yahoo Canada Finance
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Yahoo Canada Finance
Notre Dame Cathedral's reopening spectacle capped a stellar year for luxury house LVMH - Yahoo Canada Finance
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance - The Manila Times
Polyrizon Strengthens Leadership Team with Key Regulatory Affairs VP Appointment from Eurofins - StockTitan
Polyrizon Ltd (PLRZ) 財務データ
Polyrizon Ltd (PLRZ) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
4.02%
0.32%
大文字化:
|
ボリューム (24 時間):